- Conditions
- Body Weights and Measures, Body Weight in the Overweight and Obese Class - I Population, Weight Estimation, Emergency Drug Dosing
- Interventions
- 3D camera weight estimate, Standard methods of weight estimation
- Diagnostic Test
- Lead sponsor
- Florida Atlantic University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 3,392
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
- Interventions
- VE303, Placebo
- Biological
- Lead sponsor
- Vedanta Biosciences, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 852 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
- Conditions
- Cigarette Smoking
- Interventions
- Extended Care Management, Standard Care
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, 3'-deoxy-3'-[18F]fluorothymidine, pharmacological study, Mibefradil
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 4 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Bitopertin, Placebo, SSRI
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 27
- States / cities
- Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Specimen Collection, Questionnaires
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Kidney Transplant, Urinary Tract Infection(UTI), Antibiotic Prophylaxis, Remote Patient Monitoring, Feasibility Pilot Study
- Interventions
- Trimethoprim-Sulfamethoxazole (TMP-SMX), Usual Care
- Drug · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 12 Years to 29 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2028 – 2033
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
- Interventions
- Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT), Metastasis directed radiotherapy (MDRT)
- Drug · Other · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Cleveland, Ohio • Madison, Wisconsin
- Conditions
- Heart Failure
- Interventions
- Usual Care, Biomarker-guided care NT-proBNP
- Other · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 894 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Sacramento, California • San Diego, California + 33 more
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction
- Interventions
- Best Practice Alert (BPA), In-Basket Message
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy
- Biological · Procedure
- Lead sponsor
- Ashutosh Kumar Tewari
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma, Sinonasal Undifferentiated Carcinoma, Locally Advanced Head and Neck Cancer
- Interventions
- Toripalimab, Carboplatin, Docetaxel, Radiation Therapy, Cisplatin
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Olfactory Dysfunction, COVID-19
- Interventions
- Acupuncture Therapy, Budesonide, Olfactory Training
- Device · Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Thyroid Cancer, Thyroid, Refractory Thyroid Cancer
- Interventions
- Surveillance Visit
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumors
- Interventions
- M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen
- Drug · Radiation
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Traumatic Rib Fracture
- Interventions
- Paravertebral Block, Intercostal Nerve Block, Epidural Block
- Procedure
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Medication Administered in Error
- Interventions
- HELPix, HELPix+Tech
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ED Patients With Chronic Medical Illnesses
- Interventions
- ED to home care transition, Usual Care
- Behavioral · Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Jacksonville, Florida
- Conditions
- Uterine Atony, Uterine Atony With Hemorrhage, Cesarean Section Complications
- Interventions
- Calcium Chloride, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease
- Interventions
- Siltuximab, Normal Saline
- Drug · Other
- Lead sponsor
- RECORDATI GROUP
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Lansing, Michigan • Charlotte, North Carolina
- Conditions
- Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Interventions
- Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel., Atezolizumab, Lurbinectedin, Irinotecan (drug), Topotecan
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Wilson Disease
- Interventions
- ALXN1840, SoC Therapy
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more
- Conditions
- System; Lupus Erythematosus
- Interventions
- Low Dose Mesenchymal Stem Cells (MSCs)
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Charleston, South Carolina
- Conditions
- Substance Use Disorders, Drug Abuse, Alcohol Abuse, Posttraumatic Stress Disorder, PTSD, Recidivism, Depression
- Interventions
- Cognitive Processing Therapy, Control Group
- Behavioral
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Osceola, Arkansas • West Memphis, Arkansas